Renal Cell Carcinoma
Conditions
Brief summary
Disease Free Survival - defined as the interval from randomisation to first evidence of local recurrence, new primary RCC, distant metastases, or death from any cause, whichever occurs first., Overall Survival - defined as all-cause mortality, the time from randomisation to death from any cause (including RCC).
Detailed description
Metastasis Free Survival (MFS), defined as the interval from randomisation to first evidence of metastases or death from RCC., RCC specific survival time, defined as the time from randomisation to death from RCC., Quality of life, Toxicity, Patient preferences for adjuvant immunotherapy
Interventions
DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.
DRUGIMJUDO 20 mg/ml concentrate for solution for infusion.
Sponsors
University College London
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Free Survival - defined as the interval from randomisation to first evidence of local recurrence, new primary RCC, distant metastases, or death from any cause, whichever occurs first., Overall Survival - defined as all-cause mortality, the time from randomisation to death from any cause (including RCC). | — |
Secondary
| Measure | Time frame |
|---|---|
| Metastasis Free Survival (MFS), defined as the interval from randomisation to first evidence of metastases or death from RCC., RCC specific survival time, defined as the time from randomisation to death from RCC., Quality of life, Toxicity, Patient preferences for adjuvant immunotherapy | — |
Countries
France, Spain
Outcome results
None listed